Vascular targeting in pancreatic cancer: The novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models

Neoplasia

Volumn 7, Issue 10, 2005, Pages 957-966

  Kleespies, Axel ^a   Köhl, Gudrun ^b   Friedrich, Michael ^b   Ryan, Anderson J ^c   Barge, Alan ^c   Jauch, Karl Walter ^a   Bruns, Christiane J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cytoskeleton; Dorsal skinfold chamber; Orthotopic tumor model; Pancreatic cancer; Vascular targeting

Indexed keywords

GEMCITABINE; N ACETYLCOLCHINOL PHOSPHATE; TUBULIN; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; COLORING AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; N ACETYLCOCHINOL O PHOSPHATE; N-ACETYLCOCHINOL-O-PHOSPHATE; ORGANOPHOSPHORUS COMPOUND; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO CULTURE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR MODEL; TUMOR NECROSIS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL CULTURE; CHEMICAL MODEL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; HUMAN; LIVER; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; UMBILICAL VEIN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; COLORING AGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, CHEMICAL; NECROSIS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PANCREATIC NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TUBULIN; UMBILICAL VEINS;

EID: 33644876060     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05304     Document Type: Article

References (35)

1. Denekamp J (1993). Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66, 181-196.
2. Folkman J (1995). Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333, 1757-1763.
3. Chaplin DJ and Dougherty GJ (1999). Tumour vasculature as a target for cancer therapy. Br J Cancer 80 (Suppl 1), 57-64.
4. Thorpe PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
5. Siemann DW, Chaplin DJ, and Horsman MR (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499.
6. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. (2002). ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62, 7247-7253.
7. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, and Giavazzi R (2003). Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63, 1534-1537.
8. Rowinsky EK, Cazenave LA, and Donehower RC (1990). Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82, 1247-1259.
9. Hill SA, Sampson LE, and Chaplin DJ (1995). Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63, 119-123.
10. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, and Ryan AJ (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8, 1974-1983.
11. Horsman MR and Murata R (2003). Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57, 1047-1055.
12. Varghese HJ, Mackenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, and Chambers AF (2004). In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the antiangiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 7, 57-64.
13. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, et al. (2004). Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3, 977-983.
14. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, and Sone S (2004). Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 10, 7671-7676.
15. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, and Dicker AP (2005). Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11, 835-842.
16. Rocha Lima CM and Centeno B (2002). Update on pancreatic cancer. Curr Opin Oncol 14, 424-430.
17. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, and Fidler IJ (1999). In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50-62.
18. Tarboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti M, et al. (2002). Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8, 1182-1188.
19. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Tarboletti G, and Giavazzi R (2003). Vascular targeting activity of ZD6126, a novel tubulin binding agent. Cancer Res 63, 1534-1537.
20. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M, and Bruns CJ (2004). Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10, 8028-8036.
21. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
22. Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, and Ellis LM (2002). Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102, 101-108.
23. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, and Fidler IJ (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60, 2926-2935.
24. Asaishi K, Endrich B, Gotz A, and Messmer K (1981). Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 41, 1898-1904.
25. Guba M, Cernaianu G, Koehl G, Geissler EK, Jauch KW, Anthuber M, Falk W, and Steinbauer M (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 61, 1575-1579.
26. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-135.
27. Horner SA, Gould S, Noakes JP, Rattray NJ, Allen SL, Zotova E, and Arezzo JC (2004). Lack of neurotoxicity of the vascular i.v. dosing in the rat. Mol Cancer Ther 3, 783-791.
28. Kleespies A, Guba M, Jauch KW, and Bruns CJ (2004). Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87, 95-104.
29. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
30. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, et al. (2004). Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10, 3650-3657.
31. McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, et al. (2004). ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. Br J Cancer 90, 705-711.
32. Alitalo K and Carmeliet P (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227.
33. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886.
34. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, and Fidler IJ (2001). Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16, 359-370.
35. Siemann DW and Rojiani AM (2002). Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54, 1512-1517.